Amphastar Pharmaceuticals (AMPH) Short-Term Debt repayments (2013 - 2023)

Amphastar Pharmaceuticals (AMPH) recorded quarterly Short-Term Debt repayments of $125.0 million in Q2 2023, up 32199.74% quarter-over-quarter from $387000.0 in Q3 2021.

Amphastar Pharmaceuticals (AMPH) Short-Term Debt repayments (2013 - 2023) Analysis & Trends

Amphastar Pharmaceuticals' Short-Term Debt repayments history runs 4 years deep, the most recent figure standing at $125.0 million for Q2 2023.

  • In Q2 2023, Short-Term Debt repayments changed N/A year-over-year to $125.0 million; the TTM figure through Jun 2023 stood at $125.4 million (changed N/A YoY), while the FY2021 annual figure was $1.2 million, changed N/A from the prior year.
  • Short-Term Debt repayments was $125.0 million for Q2 2023 at Amphastar Pharmaceuticals, up from $387000.0 in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $125.0 million in Q2 2023 to a low of $387000.0 in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn -
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -
10 Amphastar Pharmaceuticals 914.14 Mn 914.14 Mn 70.32 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2023 125.00 Mn
Jun 30, 2023 125.00 Mn
Sep 30, 2021 387,000.00
Sep 30, 2021 387,000.00
Jun 30, 2014 25.00 Mn
Jun 30, 2014 25.00 Mn
Mar 31, 2014 15.00 Mn
Mar 31, 2014 15.00 Mn
Dec 31, 2013 16.00 Mn
Dec 31, 2013 16.00 Mn
Sep 30, 2013 15.00 Mn
Sep 30, 2013 15.00 Mn